Loading…
Biotech Next Gen 2021 has ended
Back To Schedule
Tuesday, June 22 • 1:00pm - 1:50pm
What’s the next target in oncology?

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Feedback form is now closed.
Immuno-oncology drugs have stormed the cancer field, but a cadence of targeted cancer drugs have hit the market, too, and more are on their way. KRAS may be the most obvious example of a new cancer target, but there’s also TIGIT, CD47, new CTLA approaches and kinase inhibitors 2.0—to name a few. We’ll dig into the hottest targets with companies pursuing them and experts watching them line up.
Moderator
avatar for Amirah Al Idrus

Amirah Al Idrus

Senior Writer, Fierce Biotech
Amirah Al Idrus is an editor with the Life Sciences group covering biotech, medtech and occasionally, biotech research. She started her career at The Center for Public Integrity, where she was on a team that earned an Al Neuharth Innovation in Investigative Award for their work covering how companies profit from the privatization of prisons. When she’s not working, Amirah spends her time playing rugby, trying to keep her plants alive and baking (and eating) pies... Read More →

Speakers
avatar for Kristen Hege, M.D.

Kristen Hege, M.D.

SVP, Early Clinical Development, Oncology/Hematology and Cell Therapy, Bristol Myers Squibb
Dr. Hege is SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb (BMS) where she is responsible for advancing a pipeline of small molecules, biologics and cell therapies from first-in-human studies through clinical proof-of-concept. In additon... Read More →
avatar for Camille Hertzka

Camille Hertzka

Head of Medical Affairs, US Oncology, AstraZeneca
Camille Hertzka is Head of Medical Affairs, US Oncology at AstraZeneca. A scientist by training, Camille has more than 15 years of industry experience in the oncology space both in Medical Affairs and Research & Development. Camille leads the teams that are responsible for the development... Read More →
avatar for Eric Rubin, M.D.

Eric Rubin, M.D.

SVP & Therapeutic Area Head, Oncology Early Development, Merck Research Labs
 Dr. Rubin has focused on cancer drug development for over 25 years, initially as a faculty member at the Dana-Farber Cancer Institute, then as a senior leader of the Cancer Institute of New Jersey, where he served as the Director of the Investigational Therapeutics Division of that... Read More →
avatar for Timothy A. Yap, M.B.B.S., Ph.D., F.R.C.P.

Timothy A. Yap, M.B.B.S., Ph.D., F.R.C.P.

Associate Professor of Investigational Cancer Therapeutics; Medical Director of the Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center
Dr. Timothy A. Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical... Read More →

Tuesday June 22, 2021 1:00pm - 1:50pm EDT
Virtual
  Panel Discussions

Attendees (27)